Selected reaction monitoring assays in mesenchymal stem cells from osteoarthritis patients by Camafeita, Emilio et al.
CLINICAL
PROTEOMICS
Camafeita et al. Clinical Proteomics 2014, 11:33
http://www.clinicalproteomicsjournal.com/content/11/1/33LETTER TO THE EDITOR Open AccessSelected reaction monitoring assays in
mesenchymal stem cells from osteoarthritis
patients
Emilio Camafeita1, José-Ramón Lamas2, Enrique Calvo1, Pilar Tornero-Esteban2, Juan-Antonio López1
and Benjamín Fernández-Gutiérrez2*Abstract
Osteoarthritis (OA) is considered the most prevalent form of arthritis. The aim of this study was to verify potential
protein OA biomarkers by applying Selected Reaction Monitoring (SRM) assays to protein extracts obtained from
Bone Marrow-Mesenchymal Stem Cells (BM-MSCs) isolated from OA patients.
BM aspirates were obtained from the femoral channel of OA patients at the time of surgery and from the femoral
channel of hip fracture subjects without OA during hip joint replacement surgery for the treatment of subcapital fracture.
SRM results verified the differential expression of several protein biomarkers in BM-MSCs from OA patients.
Keywords: Osteoarthritis, Mesenchymal stem cells, Selected reaction monitoringProteomic approaches have proposed numerous protein
factors potentially involved in pathological processes in-
cluding osteoarthritis (OA) [1], the most prevalent rheum-
atic disease [2]. While the validation of such potential
biomarkers has traditionally relied on immunoassays,
specific antibodies may not be available [3], and se-
lected reaction monitoring (SRM) has recently emerged
as a promising application in medical screening due to
its ability for multiplexed, high-throughput analysis as
well as its sensitivity and quantitation capacity [4,5]. In
a previous work we have described the regulation of
several proteins in bone marrow mesenchymal stem
cells (BM-MSCs) from OA patients [6]. The potential
application of MSCs in cell therapies aimed at rheum-
atic diseases has aroused great interest [7], and our re-
sults suggested the preactivation of these cells by
signaling events produced by the subchondral bone. To
verify these potential protein OA biomarkers, SRM as-
says have now been applied to protein extracts from
BM-MSCs isolated from OA patients.
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(age: 52 and 89 years) and three hip fracture subjects* Correspondence: benjamin.fernandez@salud.madrid.org
2Rheumatology Service, Hospital Clínico San Carlos, Profesor Martín Lagos s/n,
Madrid E-28040, Spain
Full list of author information is available at the end of the article
© 2014 Camafeita et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.without OA (mean age 73.3 years, range 47–90) during
hip joint replacement surgery. Hip fracture subjects with-
out OA had a densitometric T-score > 2.5 SD (Hologic
QDR-4500C) performed after surgery. All samples were
obtained after patients gave their informed consent, and
this study was approved by the local institutional ethics
committee. After culturing the cell-containing fraction of
BM aspirates as previously described [6], five pellets of ap-
proximately 2 × 106 confluent cells at the third passage
were obtained. Then the cells were lysed, protein concen-
tration was measured as previously described [6] and the
five resulting protein extracts (110 μg each) were sepa-
rated by SDS-PAGE on a 12% polyacrylamide gel. The
proteins were stained and digested with trypsin as de-
scribed in [6].
Since peptide precursor and fragment data from our pre-
vious, DIGE-based experiments [6] were generated using
MALDI ionization, additional data based on ESI were ne-
cessary to choose the most appropriate transition pairs.
For that, prior to SRM half the sample amount (55 μg) was
subject to shotgun analysis on an LTQ-Orbitrap XL ETD
(Thermo-Fisher) ESI mass spectrometer as described pre-
viously [8]. The precursor-diagnostic transitions to be
assayed by SRM were chosen by carefully examining the
MS/MS spectra corresponding to the peptides most reli-
ably identified in the shotgun analysis (data not shown). Toral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Precursor-fragment transitions significantly different between OA and control patients




Ratio p-value Ratio p-value
Tubulin α6 DVNAAIATIK 508.3(+2) 801.4(y8) a
−1,76 0.007 −2.17
0.032
LISQIVSSITASLR 744.4(+2) 933.5(y9) b 0.017
Cathepsin B chain B LPASFDAR 438.7(+2) 666.3(y6) c
+1.90 0.036 +4.21
0.005
NGPVEGAFSVYSDFLLYK 1003.5(+2) 1048.5(y8) d 0.031
Dihydropyrimidinase-like 2 variant VFNLYPR 454.7(+2) 662.3(y5) e
−2.52 0.028 −4.25
0.006
IAVGSDADLVIWDPDSVK 950.5(+2) 545.7(y6) f 0.033
IAVGSDADLVIWDPDSVK 950.5(+2) 846.4(y7) g 0.008
L-caldesmon II GNVFSSPTAAGTPNK 724.4(+2) 856.5(y9) h −1,93 0.008 −2.89 0.009
Destrin isoform B YALYDASFETK 654.3(+2) 797.4(y7) i +4.30 0.006 +4.02 0.025
aPeptide m/z value filtered in the fisrt quadrupole; bFragment m/z value filtered in the third quadrupole; cAs depicted in Figure 1; dFrom the comparative analysis
of differential protein expression [6]; eThe symbols ‘ + ’ and ‘-’ indicate increased or decreased abundance in OA samples relative to controls, respectively; DIGE,
differential in-gel electrophoresis; m/z, mass-to-charge ratio; OA, osteoarthritis; SRM, selected reaction monitoring; XIC, extracted ion chromatogram.
Figure 1 SRM assays with proteins previously found regulated in MSCs from osteoarthritic patients. For the measurements which produced
significant differences (p < 0.05) between patients ( ) and controls ( ) the extracted ion chromatogram (XIC) is shown together
with maximum, minimum and average ± SD values obtained by measuring peak areas corresponding to the transitions detailed in Table 1 (a-i). Two
transitions from pyruvate kinase peptides (GDLGIEIPAEK: 571.3(+2)/686.4(y6); IYVDDGLISLQVK: 731.9(+2)/574.4(y5)) were used to normalize the data.
ct, controls; MSCs, mesenchymal stem cells; oa, osteoarthritis; SD, standard deviation.
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the performance of the mass spectrometer, two to three
transition pairs were chosen for eight out of the 38 pro-
teins previously found regulated in the MSCs from OA pa-
tients [6]. A 4000 Q-Trap (AB Sciex) hybrid instrument
was used for the multiplexed, non-time-scheduled SRM
analysis of the above selected pairs followed by enhanced
resolution scans (for charge and mass determination) and
enhanced product ion scans (for induced fragmentation)
along a single chromatographic run (80 min) per sample
(55 μg). The analysis of mass spectra was carried out using
the Analyst 1.5 software (AB Sciex). Relative peptide quan-
tification was performed by measuring the area of the
extracted ion chromatogram (XIC) peaks from selected
precursor ions. Two transitions from pyruvate kinase pep-
tides that showed comparable spectral counts across the
two OA and the three control samples in the shotgun ana-
lysis were used to normalize XIC areas and to check that
retention time variability was within ±2.5 min. In addition,
the presence of the MS/MS fragmentation spectra from
the corresponding precursor ions was manually checked
along the XIC peaks to rule out interference from unre-
lated ions. The statistical comparison of the OA and con-
trol groups was performed based on parametric Student’s t
test and/or non-parametric Mann–Whitney U test. Values
with p < 0.05 were considered significant.
SRM results enabled the verification of a five-protein
set for which significant differences were measured be-
tween patients and controls (Table 1 and Figure 1). The
ratios calculated on the basis of the transition areas
shown in the corresponding XIC and box and whisker
plots (Figure 1) were comparable to those obtained by
DIGE (Table 1). Limitations of this study have arisen
from the reduced number of samples and cells available;
thus, time-scheduled assays would have enabled SRM
analysis of a much higher number of transition pairs,
therefore expanding verification to other proteins. The
availability of higher sample amounts would also enable:
i) The analysis of technical replicates to improve statis-
tical power; ii) The use of retention time standards or
reference synthetic peptides to control chromatographic
reproducibility; and iii) To minimize the use of precur-
sor peptides with sub-optimal proteotypic nature by in-
creasing sequence coverage in shotgun experiments
Based on SRM we have verified the differential expres-
sion of potential protein biomarkers in BM-MSCs from
OA patients. Results reinforce the hypothesized preacti-
vation of these cells by signaling events produced by the
subchondral bone and corroborate the feasibility of
using SRM for the quantitation of biomarker sets in
clinically relevant samples.
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